Jpmorgan Chase & CO Pyxis Oncology, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PYXS
# of Institutions
101Shares Held
28.2MCall Options Held
539KPut Options Held
54.1K-
Deep Track Capital, LP Greenwich, CT4.18MShares$6.99 Million0.57% of portfolio
-
Laurion Capital Management LP New York, NY3.63MShares$6.06 Million0.18% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$4.65 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$4.06 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.91MShares$3.18 Million0.0% of portfolio
About Pyxis Oncology, Inc.
- Ticker PYXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,096,400
- Market Cap $58.6M
- Description
- Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...